Catatonia Associated With Valbenazine Treatment

Overview of attention for article published in Journal of Clinical Psychopharmacology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 10,934 followers.

RT @JCPjournal: Vesicular monoamine transporter 2 (#VMAT2) inhibitor #valbenazine is approved by the @US_FDA for the treatment of tardive d…

Vesicular monoamine transporter 2 (#VMAT2) inhibitor #valbenazine is approved by the @US_FDA for the treatment of tardive dyskinesia. A new report in @JCPjournal describes a case of #catatonia associated with valbenazine use: https://t.co/wfN3NsHpmS htt…

Catatonia Associated With Valbenazine Treatment https://t.co/6oX3Qnw3y3

RT @JCPjournal: Catatonia Associated With Valbenazine Treatment https://t.co/6t7hXmKXEs https://t.co/54wJq9GfbR

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.